Affymetrix Files Restated Financial Statements
August 30 2006 - 5:32PM
Business Wire
Affymetrix, Inc. (Nasdaq:AFFX) announced today that it has
completed its previously announced restatement of the Company's
financial statements. The restated financial statements have been
filed with the Securities and Exchange Commission in an amended
Form 10-K/A for the year ended December 31, 2005 and an amended
Form 10-Q/A for the quarter ended March 31, 2006. The Company has
also filed its Form 10-Q for the quarter ended June 30, 2006 which
had been delayed due to the restatement. The Company is now current
in its SEC reporting obligations and, as a result, expects that the
previously disclosed Nasdaq delisting action will be terminated and
believes that the previously disclosed notice of default under the
Company's indenture has been cured. As previously disclosed, an
internal review performed under the direction of the Audit
Committee of the Board of Directors identified certain errors and
documentation lapses in the Company's historic option granting
practices but did not find any pattern or practice of
inappropriately identifying grant dates with hindsight in order to
provide "discounted" or "in-the-money" grants. The Company
concluded that as a result of a documentation lapse in July 1999,
an option grant for an aggregate of 1.99 million shares should have
been measured for accounting purposes as of a later date. In light
of the restatement required by this matter, the Company also
included in its restatement corrections relating to certain other
errors and documentation lapses in the fiscal years 1997 and 1998.
Approximately 97% of the charges relating to the restatement arose
from the documentation lapse in July 1999. The Company has
determined that the cumulative, pre-tax, non-cash, stock-based
compensation expense resulting from revised measurement dates for
options granted between 1997 and 1999 was approximately $21.5
million. Accordingly, the Company recorded stock-based compensation
expense of $0, $0, and $1.7 million for the years ended December
31, 2005, 2004 and 2003, respectively, and $19.8 million for the
five years preceding 2003, based on the vesting periods of the
respective grants. In addition, the Company recorded an income tax
benefit of $8.3 million in 2005. The adjustments increased
previously reported basic and diluted net income per common share
by $0.13 and $0.12, respectively, for the year ended December 31,
2005 and decreased basic and diluted net income per common share by
$0.03 for the year ended December 31, 2003. About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial
microarray in 1994. Since then, Affymetrix GeneChip(R) technology
has become the industry standard in molecular biology research.
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic and biotechnology companies as well as leading academic,
government and not-for-profit research institutes. More than 1,400
systems have been installed around the world and nearly 4,000
peer-reviewed papers have been published using the technology.
Affymetrix' patented photolithographic manufacturing process
provides the most information capacity available today on an array,
enabling researchers to use a whole-genome approach to analyzing
the relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The Company maintains
important sales and marketing operations in Europe and Asia and has
about 1,100 employees worldwide. For more information about
Affymetrix, please visit the Company's website at
www.affymetrix.com. All statements in this press release that are
not historical are "forward-looking statements" under the federal
securities laws. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including but not limited to the risk that further review of the
Company's financial reporting for prior periods will require
further restatement, and the other risk factors discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005 and
other SEC reports, including its Form 10-Q reports for subsequent
periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations or any change in events, conditions, or
circumstances on which any such statements are based.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024